Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. is listed today as Seaport Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2024 | $226 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Seaport Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).
SEC Form D · Oct 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2024
That is all the official record says: Seaport Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Seaport Therapeutics, Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Antony Loebel | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2026) | SEC Form 3 |
| ARCH Venture Fund XII, L.P. | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| ARCH Venture Partners XII, LLC | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| ARCH Venture Partners XII, L.P. | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Lana Gladstein | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2026) | SEC Form 3 |
| Michael Cunyuan Chen | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2026) | SEC Form 3 |
| PureTech Health PLC | Company | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| PureTech LYT, Inc. | Company | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Steven M. Paul | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.
Largest shareholders today
Institutions holding Seaport Therapeutics, Inc. shares, as of Sep 30, 2026.
- ARCH Venture Management, LLC$127 M11.76%
- General Atlantic, L.P.$123 M11.40%
- Sofinnova Investments, Inc.$72 M6.66%
- Goldman Sachs Group Inc$44 M4.08%
- TRV GP Vi, LLC$42 M3.85%
- Canada Pension Plan Investment Board$40 M3.69%
- FMR LLC$37 M3.43%
- Foresite Capital Management VI LLC$36 M3.32%
- Jpmorgan Chase & Co$32 M2.98%
- Jennison Associates LLC$23 M2.15%
- Bellevue Group AG$22 M2.05%
- Siren, L.L.C.$22 M2.05%
- BlackRock, Inc.$20 M1.83%
- Ra Capital Management, L.P.$14 M1.31%
- Price T Rowe Associates Inc /MD/$13 M1.18%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Antony Loebel | Executive officer | Oct 2024 |
| Daphne Zohar | Executive officer | Oct 2024 |
| Eric Green | Executive officer | Oct 2024 |
| Lana Gladstein | Executive officer | Oct 2024 |
| Michael Chen | Executive officer | Oct 2024 |
| Bharatt I. Chowrira | Director | Oct 2024 |
| Daphne Zohar | Director | Oct 2024 |
| David I. Wheadon | Director | Oct 2024 |
| Denice I. Torres | Director | Oct 2024 |
| Eric Elenko | Director | Oct 2024 |
| James I. Healy | Director | Oct 2024 |
| Jason I. Pitts | Director | Oct 2024 |
| Robert I. Nelsen | Director | Oct 2024 |
| Steven Paul | Director | Oct 2024 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.